Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression

International Journal of Radiation Biology

Volumn 70, Issue 3, 1996, Pages 273-280

  Lawrence, T S ^a   Davis, M A ^a   Tang, H Y ^b   Maybaum, J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE S PHASE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIZATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL SURVIVAL; DNA DAMAGE; FLOXURIDINE; GENES, P53; HT29 CELLS; HUMANS; RADIATION-SENSITIZING AGENTS; S PHASE;

EID: 0029792222     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/095530096145003     Document Type: Article

References (26)

1. CANMAN, C. E., TANG, H. Y., NORMOLLE, D. P., LAWRENCE, T. S. and MAYBAUM, J., 1992, Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity. Procedures of the National Academy of Science, 89, 10474-10478.
2. DAVIS, M. A., TANG, H. Y., MAYBAUM, J. and LAWRENCE, T. S., 1995. Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. International Journal of Radiation Biology, 67, 509-512.
3. DEWEY, W. C., LI, X. L. and WONG, R. S., 1990, Cell killing, chromosomal aberrations, and division delay as thermal sensitivity is modified during the cell cycle. Radiation Research, 122, 268-274.
4. FELDMAN, S. and SCHONTHAL, A., 1994, Negative regulation of histone H1 kinase expression by mimosine, a plant amino acid. Cancer Research, 54, 494-498.
5. FERTIL, B., DERTINGER, H., COURDI, A. and MALAISE, E. P., 1984, Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiation Research, 99, 73-84.
6. HALDANE, A., FINLAY, G. J. and BAGULEY, B. C., 1993, A comparison of the effects of aphidicolin and other inhibitors to topoisomerase II-directed cytotoxic drugs. Oncology Research, 5, 133-138.
7. ILIAKIS, G., PANTELIAS, G., OKAYASU, R. and SEANER, R., 1989, Comparative studies on repair inhibition by araA, araC and aphidicolin of radiation induced DNA and chromosome damage in rodent cells: comparison with fixation of PLD. International Journal of Radiation Oncology Biology Physics, 16, 1261-1265.
8. 1 phase of the mammalian cell cycle. Experimental Cell Research, 186, 332-339.
9. LAWRENCE, T. S., DAVIS, M. A., MAYBAUM, J., MUKHOPADHAY, S. K., STETSON, P. L., NORMOLLE, D. P., MCKEEVER, P. E. and ENSMINGER, W. D., 1992, The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer. Cancer Research, 52, 3698-3704.
10. LAWRENCE, T. S., NORMOLLE, D. P., DAVIS, M. A. and MAYBAUM, J., 1993, The use of biphasic linear ramped pulsed field gel electrophoresis to quantify DNA damage based on fragment size distribution. International Journal of Radiation Oncology Biology Physics, 27, 659-663.
11. LAWRENCE, T. S., DAVIS, M. A. and LONEY, T. L., 1996, Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Research, 56.
12. LOWE, S. W., BODIS, S., MCCLATCHEY, A., REMINGTON, L., RULEY, H. E., FISHER, D. E., HOUSMAN, D. E. and JACKS, T., 1994, P53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810.
13. MCGINN, C. J. and KINSELLA, T. J., 1992, The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Seminars in Oncology, 19, 21-28.
14. MCGINN, C. J., MILLER, E. M., LINDSTROM, M. J., KUNUGI, K. A., JOHNSTON, P. G. and KINSELLA, T. J., 1994, The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization. International Journal of Radiation Oncology Biology Physics, 30, 851-859.
15. MEDRANO, E. E. and PARDEE, A. B., 1980, Prevalent deficiency in tumor cells of cycloheximide-induced cycle arrest. Procedures of the National Academy of Science, 77, 4123-4126.
16. O'CONNOR, P. M., NIEVES-NEIRA, W., DERRIGAN, D., GOLDMAN, J., BERTRAND, R., KOHN, K. W. W. and POMMIER, Y., 1991, Aphidicolin protects non-s-phase human colon carcinoma HT-29 cells against killing by camptothecin. Procedures of the Annual Meeting of the American Society for Cancer Research, 32, P336.
17. PEDRALE-NOY, G. and SPADARI, S., 1979, Effect of aphidicolin on viral and human DNA polymerases. Biochemistry Biophysics Research Communications, 88, 1194-1202.
18. PU, T., ROBERTSON, J. M. and LAWRENCE, T. S., 1995, Current status of radiation sensitization by fluorinated pyrimidines. Oncology, 9, 707-735.
19. RODRIGUES, N. R., ROWAN, A., SMITH, M. E. F., KERR, J. B., BODMER, W. F., GANNON, J. V. and LANE, D. 1990, p53 mutations in colorectal cancer. Procedures of the National Academy of Science, 87, 7555-7559.
20. RYAN, A. J., SQUIRES, S., STRUTT, H. L. and JOHNSON, R. T., 1991, Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Research, 19, 3295-3300.
21. SINCLAIR, W. K., 1968, Cyclic x-ray responses in mammalian cells in vitro. Radiation Research, 33, 620-643.
22. TANG, H.-Y., DAVIS, M. A., STRICKFADEN, S. M., MAYBAUM, J. and LAWRENCE, T. S., 1994, Influence of cell cycle phase on radiation-induced cytotoxicity and DNA damage in human colon cancer (HT29) and Chinese hamster ovary cells. Radiation Research, 138, S109-S112.
23. TANG, H-Y., WEBER, K. L., LAWRENCE, T. S., MERCHANT, A. K., MAYBAUM, J., 1996, Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S-phase progression HT29 cells. Cancer Chemotherapy & Pharmacology, 37, 486-490.
24. TERASIMA, T. and TOLMACH, L. J., 1963, Variations in several responses of HeLa cells to X-irradiation during the division cycle. Biophysics Journal, 3, 11-33.
25. TISHLER, R. B., CALDERWOOD, S. K., COLEMAN, C. N. and PRICE, B. D., 1993, Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Research Supplement, 53, 2212-2216.
26. 1-S phase border. Cytometry, 12, 242-246.